dc.contributor.author |
Yesilkaya, S |
|
dc.contributor.author |
Acikel, C |
|
dc.contributor.author |
Fidanci, BE |
|
dc.contributor.author |
Polat, A |
|
dc.contributor.author |
Sozeri, B |
|
dc.contributor.author |
Ayaz, NA |
|
dc.contributor.author |
Makay, BB |
|
dc.contributor.author |
Simsek, D |
|
dc.contributor.author |
Akinci, N |
|
dc.contributor.author |
Ozcelik, G |
|
dc.contributor.author |
Kavukcu, S |
|
dc.contributor.author |
Emre, S |
|
dc.contributor.author |
Donmez, O |
|
dc.contributor.author |
Delibas, A |
|
dc.contributor.author |
Yuksel, S |
|
dc.contributor.author |
Berdeli, A |
|
dc.contributor.author |
Poyrazoglu, H |
|
dc.contributor.author |
Saldir, M |
|
dc.contributor.author |
Fidanci, K |
|
dc.contributor.author |
Cakar, N |
|
dc.contributor.author |
Peru, H |
|
dc.contributor.author |
Bakkaloglu, S |
|
dc.contributor.author |
Tabel, Y |
|
dc.contributor.author |
Sari, O |
|
dc.contributor.author |
Aydogan, U |
|
dc.contributor.author |
Ozenc, S |
|
dc.contributor.author |
Basbozkurt, G |
|
dc.contributor.author |
Unsal, E |
|
dc.contributor.author |
Kasapcopur, O |
|
dc.contributor.author |
Gok, F |
|
dc.contributor.author |
Ozen, S |
|
dc.contributor.author |
Demirkaya, E |
|
dc.date.accessioned |
2022-03-30T13:15:52Z |
|
dc.date.available |
2022-03-30T13:15:52Z |
|
dc.date.issued |
2015 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/59280 |
|
dc.description.abstract |
Objective. To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. |
|
dc.description.abstract |
Methods. The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. |
|
dc.description.abstract |
Results. One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11 +/- 4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.5 15, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r-0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001). |
|
dc.description.abstract |
Conclusion. Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended. |
|
dc.source |
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY |
|
dc.title |
Development of a medication adherence scale for familial Mediterranean |
|
dc.title |
fever (MASIF) in a cohort of Turkish children |
|